Citigroup Inc Standard Biotools Inc. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Standard Biotools Inc. stock. As of the latest transaction made, Citigroup Inc holds 224,827 shares of LAB stock, worth $240,564. This represents 0.0% of its overall portfolio holdings.
Number of Shares
224,827
Previous 247,855
9.29%
Holding current value
$240,564
Previous $433,000
44.11%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding LAB
# of Institutions
151Shares Held
280MCall Options Held
6KPut Options Held
36.6K-
Casdin Capital, LLC New York, NY76.1MShares$81.4 Million9.61% of portfolio
-
Viking Global Investors LP58.7MShares$62.8 Million0.21% of portfolio
-
Black Rock Inc. New York, NY21.8MShares$23.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.2MShares$18.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY10.7MShares$11.5 Million0.0% of portfolio
About STANDARD BIOTOOLS INC.
- Ticker LAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 78,654,800
- Market Cap $84.2M
- Description
- Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar ...